TY - JOUR
T1 - Heat shock protein 70 in patients with chronic heart failure
T2 - Relation to disease severity and survival
AU - Genth-Zotz, Sabine
AU - Bolger, Aidan P.
AU - Kalra, Paul R.
AU - Von Haehling, Stephan
AU - Doehner, Wolfram
AU - Coats, Andrew J S
AU - Volk, Hans Dieter
AU - Anker, Stefan D.
PY - 2004/9
Y1 - 2004/9
N2 - Background: Heat shock protein 70 (Hsp70) is essential for cellular recovery, survival and maintenance of cellular function. Research into the possible use of Hsp70 as a cytoprotective therapeutic agent is ongoing. Chronic heart failure (CHF) is a state associated with systemic inflammation, particularly in patients with cardiac cachexia. We hypothesised that circulating Hsp70 levels are elevated in patients with CHF, more so in cachechtic patients, and that Hsp70 levels would relate to mortality. Methods and results: We studied 107 patients (28 female, age 67±1 years, NYHA class 2.6±0.6 and LVEF 29±1%, mean±SEM) and 21 controls. Cardiac cachexia was present in 32 patients. Hsp70 was detectable in 41% of CHF patients and in only 10% of controls. Overall serum levels were significantly higher in CHF patients vs. controls (7.13±1.34 vs. 0.38±0.26 ng/ml, p=0.004). Hsp70 levels were also higher in patients with advanced CHF according to NYHA class or the presence of cachexia (all p0.05). During a median follow-up of 208 days (range 4-2745 days) 38 patients died. Cox proportional hazards analysis showed that increased Hsp70 did not predict survival (p=0.17). Conclusion: Hsp70 levels are elevated in CHF patients, particularly in those with cardiac cachexia and Hsp70 relates to disease severity but not to survival. The significance of the relationship of Hsp70 expression and morbidity in CHF needs further evaluation.
AB - Background: Heat shock protein 70 (Hsp70) is essential for cellular recovery, survival and maintenance of cellular function. Research into the possible use of Hsp70 as a cytoprotective therapeutic agent is ongoing. Chronic heart failure (CHF) is a state associated with systemic inflammation, particularly in patients with cardiac cachexia. We hypothesised that circulating Hsp70 levels are elevated in patients with CHF, more so in cachechtic patients, and that Hsp70 levels would relate to mortality. Methods and results: We studied 107 patients (28 female, age 67±1 years, NYHA class 2.6±0.6 and LVEF 29±1%, mean±SEM) and 21 controls. Cardiac cachexia was present in 32 patients. Hsp70 was detectable in 41% of CHF patients and in only 10% of controls. Overall serum levels were significantly higher in CHF patients vs. controls (7.13±1.34 vs. 0.38±0.26 ng/ml, p=0.004). Hsp70 levels were also higher in patients with advanced CHF according to NYHA class or the presence of cachexia (all p0.05). During a median follow-up of 208 days (range 4-2745 days) 38 patients died. Cox proportional hazards analysis showed that increased Hsp70 did not predict survival (p=0.17). Conclusion: Hsp70 levels are elevated in CHF patients, particularly in those with cardiac cachexia and Hsp70 relates to disease severity but not to survival. The significance of the relationship of Hsp70 expression and morbidity in CHF needs further evaluation.
KW - Chronic heart failure
KW - Disease severity and survival
KW - Heat shock protein70
UR - http://www.scopus.com/inward/record.url?scp=4143096014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4143096014&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2003.08.008
DO - 10.1016/j.ijcard.2003.08.008
M3 - Article
C2 - 15301893
AN - SCOPUS:4143096014
VL - 96
SP - 397
EP - 401
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 3
ER -